Tony P Tang

USPTO Granted Patents = 40 (Patent Applications = 10)

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 12.3

ph-index = 7

Forward Citations = 195(Granted Patents)

Location History:

Longmont, CO (US) (2009 - 2010)
Boudler, CO (US) (2018)
Boulder, CO (US) (2012 - 2024)

Company Filing History:

Mirati Therapeutics, Inc.

patents

6 out of 4,442

Eli Lilly and Company

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

40 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12180207 - Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases (2024-12-31),

2. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

3. 11964989 - KRas G12D inhibitors (2024-04-23),

4. 11932633 - KRas G12C inhibitors (2024-03-19),

5. 11807651 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2023-11-07),

6. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

7. 11453683 - KRas G12D inhibitors (2022-09-27),

8. 11267812 - KRAS G12C inhibitors (2022-03-08),

9. 11098064 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile (2021-08-24),

10. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2021-06-08),

11. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),

12. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),

13. 10766881 - 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases (2020-09-08),

14. 10745419 - Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (2020-08-18),

15. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors (2020-08-04),

Title: The Innovations of Tony P. Tang

Introduction

Tony P. Tang is a highly esteemed inventor based in Boulder, Colorado, known for his significant contributions to the field of pharmaceutical chemistry. With an impressive portfolio of 40 patents, he has made substantial advancements in drug discovery, particularly in targeting specific kinases that play crucial roles in various diseases.

Latest Patents

Among his latest innovations are two noteworthy patents that focus on substituted pyrazolo[1,5-a]pyridine compounds. The first patent details compounds designed as inhibitors of FGFR (Fibroblast Growth Factor Receptors) tyrosine kinases. These compounds, represented by a general formula, are intended for the treatment and prevention of diseases mediated by FGFR1, FGFR2, FGFR3, and FGFR4. Their application could significantly impact therapeutic strategies for various FGFR-related disorders. The second patent involves the same class of compounds but targets RET (REarranged during Transfection) kinase. This invention aims to provide solutions for treating diseases associated with RET, thus showcasing the potential of these inhibitors in clinical settings.

Career Highlights

Throughout his career, Tony P. Tang has collaborated with prominent companies in the biotechnology sector. He has worked with Array Biopharma Inc. and Mirati Therapeutics, Inc., where he has applied his expertise to advance therapeutic inventions. His extensive research has positioned him as a leader in pharmacological innovations, particularly in kinase inhibition.

Collaborations

In the realm of innovation, collaboration often leads to impactful results. Tony has teamed up with notable professionals such as James F. Blake and Andrew T. Metcalf. Their combined efforts have contributed to the development of pioneering therapies that aim to change the landscape of medicine.

Conclusion

Tony P. Tang's work epitomizes the spirit of innovation within the pharmaceutical realm. With a robust number of patents reflecting his ingenuity, he continues to explore new avenues in disease treatment through his focused research on kinase inhibitors. The implications of his inventions not only advance scientific knowledge but also hold great promise for therapeutic applications in the future.

This text is generated by artificial intelligence and may not be accurate.